microRNA-155, induced by interleukin-1ss, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells
Molecular Characteristics Molecular Type: Triple synthetic peptide research blend Structure: Linear synthetic peptides CAS Identifiers: 446262-90-4 (CJC-1295), 170851-70-4 (Ipamorelin), 158861-67-7 (GHRP-2) Form: Lyophilized powder blend Molecular Weight: Sequence-dependent Stability: High when stored under recommended laboratory conditions Stability Profile and Storage Recommendations Supplied as a lyophilized peptide blend for long-term stability Recommended storage temperature: 20C Protect from humidity and direct light exposure Avoid repeated freezethaw cycles Reconstituted solutions remain stable for approximately 2448 hours under refrigeration Solubility and Reconstitution Options Bacteriostatic water Sterile saline solutions Buffered aqueous solutions Acidic buffer systems Analytical-grade organic solvents Technical Specifications product Name CJC-1295 + Ipamorelin + GHRP-2 Blend brand Biopeptides cas 446262-90-4 / 170851-70-4 / 158861-67-7 purity 99% (HPLC verified) unit Size Blend vial form Lyophilized powder synthesis Solid-Phase Peptide Synthesis (SPPS) analytical HPLC, Mass Spectrometry, UV Spectrophotometry molecular Structure Linear synthetic peptide blend stability High when stored appropriately Quality Control and Analytical Validation High-Performance Liquid Chromatography (HPLC) purity verification Mass Spectrometry molecular identity confirmation UV spectrophotometric concentration analysis Batch-to-batch consistency validation Endotoxin and microbial contamination screening Regulatory Status and Intended Use The CJC-1295 + Ipamorelin + GHRP-2 Blend is supplied strictly for laboratory research use only
K-YL: Resources, Software, Supervision, Validation, Writing review & editing
Your physician recommends the best option
Histopathological Changes in Placentas of Gestational Hypertension Women Alaa N
Direct feedback from their workforce provides insight into how obesity impacts operations and morale, influencing their willingness to cover newer, more expensive therapies like GLP-1s
